Drug/Small Molecule:
pravastatin

PharmGKB contains no dosing guidelines for this drug/small molecule. To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB gathers information regarding PGx on FDA drug labels from the FDA's "Table of Pharmacogenomic Biomarkers in Drug Labels", and from FDA-approved FDA and EMA-approved (European Medicines Agency) EMA labels brought to our attention. Excerpts from the label and downloadable highlighted label PDFs are manually curated by PharmGKB.

Please note that some drugs may have been removed from or added to the FDA's "Table of Pharmacogenomic Biomarkers in Drug Labels" without our knowledge. We periodically check the table for additions to this table and update PharmGKB accordingly.

There is currently no such list for European drug labels - we are working with the EMA to establish a list of European Public Assessment Reports (EPAR)s that contain PGx information. We are constructing this list by initially searching for drugs for which we have PGx-containing FDA drug labels - of these 44 EMA EPARs were identified and are being curated for pgx information.

We welcome any information regarding drug labels containing PGx information approved by the FDA, EMA or other Medicine Agencies around the world - please contact feedback.



last updated 12/20/2013

FDA Label for pravastatin and APOE

Informative PGx

Summary

The FDA drug label contains pharmacogenetic information regarding response results in patients with APOE genotype E2/E2 and Fredrickson Type III dysbetalipoproteinemia. This drug-biomarkers pair was previously in the FDA's "Table of Pharmacogenomic Biomarkers in Drug Labels" but has subsequently been removed, and replaced by pravastatin and LDLR.

There's more of this label. Read more.


last updated 12/20/2013

FDA Label for pravastatin and LDLR

This label is on the FDA Biomarker List
Informative PGx

Summary

The FDA-approved drug label for pravastatin (PRAVACHOL) states that the drug is intended for patients with familial hypercholesterolemia (Fredrickson Type IIa), among other indications. Familial hypercholesterolemia is commonly caused by mutations in the LDLR (low density lipoprotein receptor) gene; pravastatin has only been evaluated in patients with heterozygous familial hypercholesterolemia (i.e. patients with only one abnormal copy of the LDLR gene).

There's more of this label. Read more.



PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Gene?

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

Gene ? Variant?
(138)
Alternate Names / Tag SNPs ? Drugs ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available CA VA APOE E2 N/A N/A N/A
No VIP available CA No VIP available APOE E3 N/A N/A N/A
No VIP available CA VA APOE E4 N/A N/A N/A
No VIP available No VIP available VA SLCO1B1 *1 N/A N/A N/A
No VIP available CA VA SLCO1B1 *1A N/A N/A N/A
No VIP available CA No VIP available SLCO1B1 *1B N/A N/A N/A
No VIP available No VIP available VA SLCO1B1 *5 N/A N/A N/A
No VIP available CA VA SLCO1B1 *15 N/A N/A N/A
No VIP available No Clinical Annotations available VA
rs1045642 208920T>A, 208920T>C, 25171488A>G, 25171488A>T, 3435T>A, 3435T>C, 87138645A>G, 87138645A>T, ABCB1*6, ABCB1: 3435C>T, ABCB1: C3435T, ABCB1: c.3435C>T, ABCB1:3435C>T, Ile1145=, Ile1145Ile, MDR1 3435C>T, MDR1 C3435T, PGP C3435T, c.3435C>T, mRNA 3853C>T
A > T
A > G
Synonymous
Ile1145Ile
No VIP available No Clinical Annotations available VA
rs113646094
C > G
Synonymous
Thr482Thr
No VIP available No Clinical Annotations available VA
rs1150226 -256A>G, -489A>G, 113845541A>G, 17407957A>G, 4745A>G
A > G
5' Flanking
No VIP available No Clinical Annotations available VA
rs11666735 27665131G>A, 301G>A, 337G>A, 35-2461G>A, 530732A>A, 55396913G>A, 789866G>A, Asp101Asn, Asp113Asn, Asp92Asn, NC_000019.9:g.55396913G>A, NM_002000.2:c.337G>A, NM_133272.2:c.301G>A, NP_001991.1:p.Asp113Asn, NP_579806.1:p.Asp101Asn
A > G
Missense
Asp113Asn
No VIP available CA VA
rs12003906 107645477G>C, 107645477G>T, 303-39C>A, 303-39C>G, 36810009G>C, 36810009G>T, 49960C>A, 49960C>G
G > T
G > C
Intronic
No VIP available No Clinical Annotations available VA
rs140700 24566G>A, 28543389C>T, 3280383C>T, 838-155G>A
C > T
Intronic
No VIP available No Clinical Annotations available VA
rs1433099 *666T>C, 11242658T>C, 2505460T>C, 47602T>C
T > C
3' UTR
No VIP available No Clinical Annotations available VA
rs1440451 154868879G>C, 498245G>C, 741+5529G>C
G > C
Intronic
No VIP available CA VA
rs16944 -598T>C, 113594867A>G, 3343530A>G, 4490T>C, IL1B: -511 C/T
A > G
5' Flanking
No VIP available No Clinical Annotations available VA
rs17222723 101595996T>A, 3563T>A, 52400460T>A, 58534T>A, ABCC2 rs8187694, MRP2 Val1188Glu, Val1188Glu
T > A
Missense
Val1188Glu
rs17238540 2298+117T>G, 2457+117T>G, 25249857T>G, 27506T>G, 74655498T>G, HMGCR:SNP 29
T > G
Intronic
rs17244841 14863A>T, 25237214A>T, 451-174A>T, 74642855A>T, HMGCR:SNP 12
A > T
Intronic
No VIP available CA VA
rs17655652 -133A>G, 44570991T>C, 44580991T>C, 4924A>G
T > C
5' Flanking
No VIP available CA VA
rs1799752 16457_16458insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, 2306-119_2306-118insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, 26840042_26840043insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, 584-119_584-118insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, 61565890_61565891insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, ACE D/I
- > ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC
Intronic
No VIP available No Clinical Annotations available VA
rs1800588 -557C>T, 29514232C>T, 4501C>T, 58723675C>T
C > T
5' Flanking
No VIP available CA VA
rs1800591 -101-478G>T, -493 GT, 100495488G>T, 15249G>T, 25043209G>T
G > T
Intronic
No VIP available No Clinical Annotations available VA
rs1801131 1040A>C, 11208431T>G, 11794419T>G, 1286A>C, 1409A>C, 16685A>C, A1298C, Glu347Ala, Glu429Ala, Glu470Ala, MTHFR:1298A>C
T > G
Not Available
Glu347Ala
No VIP available CA VA
rs1801133 11210333G>A, 11796321G>A, 14783C>T, 419C>T, 665C>T, 677C>T, 788C>T, A222V, Ala140Val, Ala222Val, Ala263Val, C677T, MTHFR: c.677C>T, MTHFR:667C>T, p.A222V
G > A
Not Available
Ala140Val
No VIP available No Clinical Annotations available VA
rs1805054 19992513C>T, 267C>T, 6672601C>T, Tyr89=
C > T
Not Available
No VIP available No Clinical Annotations available VA
rs1891311 -1188T>C, 4056T>C, 43423080A>G, 92618616A>G
A > G
5' Flanking
No VIP available CA VA
rs1935349 28329G>A, 43398807C>T, 539+22547G>A, 92594343C>T
C > T
Intronic
No VIP available No Clinical Annotations available VA
rs2020933 -221+876T>A, 28561755A>T, 3298749A>T, 6200T>A
A > T
Intronic
No VIP available CA VA
rs2032582 186947T>A, 186947T>G, 25193461A>C, 25193461A>T, 2677A, 2677G, 2677T, 2677T>A, 2677T>G, 3095G>T/A, 87160618A>C, 87160618A>T, 893 Ala, 893 Ser, 893 Thr, ABCB1*7, ABCB1: 2677G>T/A, ABCB1: 2677T/A>G, ABCB1: A893S, ABCB1: G2677T/A, ABCB1: c.2677G>T/A, ABCB1:2677G>A/T, ABCB1:2677G>T/A, ABCB1:A893T, Ala893Ser/Thr, MDR1, MDR1 G2677T/A, Ser893Ala, Ser893Thr, mRNA 3095G>T/A, p.Ala893Ser/Thr
A > C
A > T
Missense
Ser893Ala
Ser893Thr
No VIP available CA VA
rs20455 2155T>C, 39265078A>G, 39325078A>G, KIF6:Trp719Arg, Trp719Arg
A > G
Missense
Trp719Arg
No VIP available CA VA
rs2230806 107620867C>T, 36785399C>T, 656G>A, 74570G>A, ABCA1:Arg219Lys, Arg219Lys
C > T
Missense
Arg219Lys
No VIP available No Clinical Annotations available VA
rs2231137 13608835C>T, 23898G>A, 34G>A, 89061114C>T, ABCG2:V12M, Val12Met
C > T
Missense
Val12Met
No VIP available No Clinical Annotations available VA
rs2231142 13600044G>T, 32689C>A, 421C>A, 89052323G>T, ABCG2: Q141K, ABCG2:421C>A, ABCG2:Q141K, ABCG2:c.421C>A, Gln141Lys, rs2231142
G > T
Missense
Gln141Lys
No VIP available No Clinical Annotations available VA
rs2273697 101563815G>A, 1249G>A, 26353G>A, 52368279G>A, ABCC2: c.1249G>A, ABCC2:1249G>A, ABCC2:V417I, ABCC2:c.1249G>A, Val417Ile, p.V417I
G > A
Missense
Val417Ile
No VIP available CA VA
rs2276307 113803887A>G, 17366303A>G, 33299A>G, 696+72A>G
A > G
Intronic
rs2306283 14089862A>G, 21329738A>G, 388A>G, 50611A>G, Asn130Asp, SLCO1B1*1B
A > G
Missense
Asn130Asp
No VIP available No Clinical Annotations available VA
rs2738466 *773A>G, 11242765A>G, 2505567A>G, 47709A>G
A > G
3' UTR
No VIP available CA VA
rs3025058 -1672_-1671insT, 102715948_102715949insA, 13452_13453insA, 3394_3395insT, 5A>6A, 6278364_6278365insA
- > A
Not Available
No VIP available CA VA
rs328 1421C>G, 19819724C>G, 28143C>G, 7677870C>G, Ser474Ter
C > G
Stop Codon
Ser474null
No VIP available No Clinical Annotations available VA
rs3758987 -381T>C, 113775275T>C, 17337691T>C, 4687T>C
T > C
5' Flanking
VIP No Clinical Annotations available No Variant Annotations available
rs3846662 1564-106A>G, 1722+45A>G, 23092A>G, 25245443A>G, 74651084A>G
A > G
Intronic
rs4149015 -910G>A, 14043446G>A, 21283322G>A, 4195G>A, SLCO1B1:11187G>A, SLCO1B1:G-11187A
G > A
5' Flanking
rs4149056 14091673T>C, 21331549T>C, 521T>C, 52422T>C, SLCO1B1*5, Val174Ala
T > C
Missense
Val174Ala
No VIP available CA VA
rs428785 13878466C>G, 28216595C>G, 679G>C, Ala227Pro
C > G
Missense
Ala227Pro
No VIP available No Clinical Annotations available VA
rs4341 16557G>C, 2306-19G>C, 26840142G>C, 584-19G>C, 61565990G>C
G > C
Intronic
No VIP available No Clinical Annotations available VA
rs4693075 18900C>G, 779-1022C>G, 84192168G>C, 8739889G>C
G > C
Intronic
No VIP available CA VA
rs4986790 1020A>G, 120475302A>G, 1307A>G, 13843A>G, 296A>G, 49639834A>G, 776A>G, 896A>G, Asp259Gly, Asp299Gly, Asp99Gly, TLR4: D299G
A > G
Missense
Asp99Gly
No VIP available No Clinical Annotations available VA
rs4986791 1076C>T, 1196C>T, 120475602C>T, 1320C>T, 14143C>T, 1607C>T, 49640134C>T, 596C>T, TLR4: T399I, Thr199Ile, Thr359Ile, Thr399Ile
C > T
Missense
Thr199Ile
No VIP available No Clinical Annotations available VA
rs539748 -147+2217T>C, -238+2217T>C, 113821349T>C, 253681T>C, 7799T>C
C > T
Intronic
No VIP available No Clinical Annotations available VA
rs6312 -344G>A, 145G>A, 28450824C>T, 47470824C>T, 5346G>A, Asp49Asn
C > T
Missense
Asp49Asn
No VIP available No Clinical Annotations available VA
rs6318 113965735G>C, 152185G>C, 398067G>C, 68G>C, Cys23Ser, HTR2C:23Ser, HTR2C:Cys23Ser
C > G
Missense
Cys23Ser
No VIP available No Clinical Annotations available VA
rs659734 28415283G>A, 362-25509C>T, 40887C>T, 47435283G>A, 614-25509C>T
G > A
Intronic
No VIP available No Clinical Annotations available VA
rs670 -113G>A, 116708413C>T, 20270829C>T, 4926G>A
C > T
5' Flanking
No VIP available No Clinical Annotations available VA
rs676643 -628C>T, 10201428G>A, 23521340G>A
G > A
5' Flanking
No VIP available CA VA
rs708272 10610487G>A, 118+279G>A, 5454G>A, 56996288G>A, A allele = B2 = not cut by TaqI, CETP:Taq1B, G allele = B1 = cut by TaqI
G > A
Intronic
No VIP available CA VA
rs7412 17680297C>T, 45412079C>T, 526C>T, 8041C>T, APOE epsilon 2, ApoE2, Arg176Cys
C > T
Missense
Arg176Cys
No VIP available No Clinical Annotations available VA
rs776746 12083G>A, 219-237G>A, 321-1G>A, 37303382C>T, 581-237G>A, 689-1G>A, 99270539C>T, CYP3A5*1, CYP3A5*3, CYP3A5*3C, CYP3A5:6986A>G, g.6986A>G, intron 3 splicing defect, rs776746 A>G
C > T
Acceptor
No VIP available No Clinical Annotations available VA
rs8014194 76720678T>A, 83-24208A>T, 95720678T>A
T > A
Intronic
No VIP available No Clinical Annotations available VA
rs8187710 101611294G>A, 4544G>A, 52415758G>A, 73832G>A, ABCC2 rs8187710, Cys1515Tyr, MRP2 Cys1515Tyr
G > A
Missense
Cys1515Tyr
No VIP available No Clinical Annotations available VA
rs9462535 2181-1490G>T, 39255792C>A, 39315792C>A
C > A
Intronic
No VIP available No Clinical Annotations available VA
rs9471077 2428+2743T>C, 39248742A>G, 39308742A>G
A > G
Intronic
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 138
2D structure from PubChem
provided by PubChem

Overview

Generic Names
  • Pravastatin Sodium
  • Pravastatina [Spanish]
  • Pravastatine [French]
  • Pravastatinum [Latin]
Trade Names
  • Compactin
  • Elisor
  • Lipostat
  • Mevalotin
  • Mevastatin
  • Mevinolin
  • Oliprevin
  • Pravachol
  • Pravaselect
  • Selectin
  • Selipran
  • Vasten
Brand Mixture Names

PharmGKB Accession Id:
PA451089

Description

Pravastatin is a cholesterol-lowering agent that belongs to a class of medications known as statins. It was derived from microbial transformation of mevastatin, the first statin discovered. It is a ring-opened dihydroxyacid with a 6'-hydroxyl group that does not require in vivo activation. Pravastatin is one of the lower potency statins; however, its increased hydrophilicity is thought to confer advantages such as minimal penetration through lipophilic membranes of peripheral cells, increased selectivity for hepatic tissues, and a reduction in side effects compared with lovastatin and simvastatin.

Source: Drug Bank

Indication

For the treatment of hypercholesterolemia and to reduce the risk of cardiovascular disease.

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Pravastatin is structurally similar to the HMG, a substituent of the endogenous substrate of HMG-CoA reductase. Unlike its parent compound, mevastatin, and statins such as lovastatin and simvastatin, pravastatin does not need to be activated in vivo. Its hydrolyzed lactone ring mimics the tetrahedral intermediate produced by the reductase allowing the agent to bind with a much greater affinity than its natural substrate. The bicyclic portion of pravastatin binds to the coenzyme A portion of the active site.

Source: Drug Bank

Pharmacology

The primary cause of cardiovascular (CV) disease is atherosclerotic plaque formation and sustained elevation of cholesterol in the blood increases the risk of CV disease. Pravastatin lowers hepatic production of cholesterol by competitively inhibiting HMG-CoA reductase, the enzyme that catalyzes the rate-limiting step in the cholesterol biosynthesis pathway via the mevalonic acid pathway. Decreased hepatic cholesterol levels causes increased uptake of low density lipoprotein (LDL) cholesterol and reduces cholesterol levels in the circulation. Pravastatin also inhibits hepatic synthesis if VLDL. At therapeutic doses, pravastatin lowers LDL cholesterol by 20-30%, increase high density lipoprotein (HDL) cholesterol by 3-10%, and decrease plasma triglycerides by 19-34%. HDL cholesterol is thought to confer protective effects against CV disease, whereas high LDL and triglyceride levels are associated with higher risk of disease.

Source: Drug Bank

Food Interaction

Avoid alcohol.|Take without regard to meals.|Avoid drastic changes in dietary habit.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Hepatic, there is a small amount of metabolism by P450 enzymes, but this effect is so minimal that inhibitory pharmacokinetic drug interactions have no real effect on its overall activity and elimination. An in vitro study which found moderate affinity for P450 2C9 (major), 2D6 and 3A4.

Source: Drug Bank

Protein Binding

50%

Source: Drug Bank

Absorption

Average oral absorption of pravastatin is 34% and absolute bioavailability is 17%.

Source: Drug Bank

Half-Life

77 hours

Source: Drug Bank

Toxicity

Side effects include diarrhea, nausea, constipation, gas abdominal pain, myopathy, myositis, rhabdomyolysis, and hepatotoxicity. LD 50=mg/kg (orally in rat)

Source: Drug Bank

Route of Elimination

Approximately 20% of a radiolabeled oral dose is excreted in urine and 70% in the feces.

Source: Drug Bank

Chemical Properties

Chemical Formula

C23H36O7

Source: Drug Bank

Isomeric SMILES

CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](CC(CC(=O)O)O)O)O

Source: OpenEye

Canonical SMILES

CC[C@H](C)C(=O)O[C@H]

Source: Drug Bank

Average Molecular Weight

424.5277

Source: Drug Bank

Monoisotopic Molecular Weight

424.246103506

Source: Drug Bank

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Ibuprofen Pathway, Pharmacokinetics
    Stylized diagram of metabolism and transport of ibuprofen in the liver and kidney.
  1. Pravastatin Pathway, Pharmacokinetics
    Drug-specific representation of the candidate genes involved in transport, metabolism and clearance.

External Pathways

Links to non-PharmGKB pathways.

PharmGKB contains no links to external pathways for this drug. To report a pathway, click here.

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

Drug Targets

Gene Description
ABCC2 (source: Drug Bank)
HMGCR (source: Drug Bank)
PGGT1B (source: Drug Bank)
RAC1 (source: Drug Bank)
SLCO1B1 (source: Drug Bank)

Curated Information ?

EvidenceDrug
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
ibuprofen

Drug Interactions

Drug Description
pravastatin Increased risk of rhabdomyolysis with this combination (source: Drug Bank)
pravastatin Increased risk of rhabdomyolysis with this combination (source: Drug Bank)
pravastatin Possible myopathy and rhabdomyolysis (source: Drug Bank)
pravastatin Possible myopathy and rhabdomyolysis (source: Drug Bank)
pravastatin Increased risk of myopathy/rhabdomyolysis (source: Drug Bank)
pravastatin Increased risk of myopathy/rhabdomyolysis (source: Drug Bank)
pravastatin Increased risk of myopathy/rhabdomyolysis (source: Drug Bank)
pravastatin Increased risk of myopathy/rhabdomyolysis (source: Drug Bank)
bezafibrate Increased risk of myopathy/rhabdomyolysis (source: Drug Bank)
bezafibrate Increased risk of myopathy/rhabdomyolysis (source: Drug Bank)
colchicine Increased risk of rhabdomyolysis with this combination (source: Drug Bank)
colchicine Increased risk of rhabdomyolysis with this combination (source: Drug Bank)
cyclosporine Possible myopathy and rhabdomyolysis (source: Drug Bank)
cyclosporine Possible myopathy and rhabdomyolysis (source: Drug Bank)
fenofibrate Increased risk of myopathy/rhabdomyolysis (source: Drug Bank)
fenofibrate Increased risk of myopathy/rhabdomyolysis (source: Drug Bank)
gemfibrozil Increased risk of myopathy/rhabdomyolysis (source: Drug Bank)
gemfibrozil Increased risk of myopathy/rhabdomyolysis (source: Drug Bank)
pravastatin Tipranavir may increase the plasma concentration of Pravastatin. Consider alternate therapy. (source: Drug Bank)

Curated Information ?

Relationships from National Drug File - Reference Terminology (NDF-RT)

May Treat
May Prevent
Contraindicated With

Publications related to pravastatin: 118

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Mechanisms and assessment of statin-related muscular adverse effects. British journal of clinical pharmacology. 2014. Moßhammer Dirk, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
SLCO1B1 Genetic Variant Associated With Statin-Induced Myopathy: A Proof of Concept Study Using the Clinical Practice Research Datalink (CPRD). Clinical pharmacology and therapeutics. 2013. Carr Daniel F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Challenges in pharmacogenetics. European journal of clinical pharmacology. 2013. Cascorbi Ingolf, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Added value of pharmacogenetic testing in predicting statin response: results from the REGRESS trial. The pharmacogenomics journal. 2012. van der Baan F H, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The effects of a SNP in SLCO1B1 on the pharmacodynamics of pravastatin. British journal of clinical pharmacology. 2011. Martin Nicholas G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Detecting Drug Interactions From Adverse-Event Reports: Interaction Between Paroxetine and Pravastatin Increases Blood Glucose Levels. Clinical pharmacology and therapeutics. 2011. Tatonetti N P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics: the genetics of variable drug responses. Circulation. 2011. Roden Dan M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics of the RNA world: structural RNA polymorphisms in drug therapy. Clinical pharmacology and therapeutics. 2011. Sadee W, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenetics and genomics. 2011. Hodges Laura M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
PharmGKB summary: methotrexate pathway. Pharmacogenetics and genomics. 2011. Mikkelsen Torben S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
PharmGKB: very important pharmacogene--HMGCR. Pharmacogenetics and genomics. 2011. Medina Marisa Wong, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic variants in the KIF6 region and coronary event reduction from statin therapy. Human genetics. 2011. Li Yonghong, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics. Pharmacogenomics. 2011. Becquemont Laurent, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Replication of LDL GWAs hits in PROSPER/PHASE as validation for future (pharmaco)genetic analyses. BMC medical genetics. 2011. Trompet Stella, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
KIF6 Trp719Arg polymorphism and the effect of statin therapy in elderly patients: results from the PROSPER study. European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology. 2010. Iakoubova Olga A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic variation in 3-hydroxy-3-methylglutaryl CoA reductase modifies the chemopreventive activity of statins for colorectal cancer. Cancer prevention research (Philadelphia, Pa.). 2010. Lipkin Steven M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic variation at the NPC1L1 gene locus, plasma lipoproteins, and heart disease risk in the elderly. Journal of lipid research. 2010. Polisecki Eliana, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effect of pravastatin therapy on coronary events in carriers of the KIF6 719Arg allele from the cholesterol and recurrent events trial. The American journal of cardiology. 2010. Shiffman Dov, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics of membrane transporters: past, present and future. Pharmacogenomics. 2010. Yee Sook Wah, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
PharmGKB very important pharmacogene: SLCO1B1. Pharmacogenetics and genomics. 2010. Oshiro Connie, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Common sequence variants in pharmacodynamic and pharmacokinetic pathway-related genes conferring LDL cholesterol response to statins. Pharmacogenomics. 2010. Chien Kuo-Liong, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Transporter pharmacogenetics and statin toxicity. Clinical pharmacology and therapeutics. 2010. Niemi M. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genome-wide association of lipid-lowering response to statins in combined study populations. PloS one. 2010. Barber Mathew J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Quantitative population pharmacokinetic analysis of pravastatin using an enterohepatic circulation model combined with pharmacogenomic Information on SLCO1B1 and ABCC2 polymorphisms. Journal of clinical pharmacology. 2009. Ide Takafumi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The pharmacogenetics of statin therapy: when the body aches, the mind will follow. Journal of the American College of Cardiology. 2009. Rossi Joseph S, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Identification of genetic variants associated with response to statin therapy. Arteriosclerosis, thrombosis, and vascular biology. 2009. Mega Jessica L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009. Hauswald Stefanie, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Statin regulation of CYP3A4 and CYP3A5 expression. Pharmacogenomics. 2009. Willrich Maria Alice Vieira, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Functional analysis of a mutation in the SLCO1B1 gene (c.1628T>G) identified in a Japanese patient with pravastatin-induced myopathy. The pharmacogenomics journal. 2009. Furihata Tomomi, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effect of R219K polymorphism of the ABCA1 gene on the lipid-lowering effect of pravastatin in Chinese patients with coronary heart disease. Clinical and experimental pharmacology & physiology. 2009. Li Jia, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The SLCO1B1*5 genetic variant is associated with statin-induced side effects. Journal of the American College of Cardiology. 2009. Voora Deepak, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The effect of nine common polymorphisms in coagulation factor genes (F2, F5, F7, F12 and F13 ) on the effectiveness of statins: the GenHAT study. Pharmacogenetics and genomics. 2009. Maitland-van der Zee Anke-Hilse, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin. Pharmacogenomics. 2009. Keskitalo Jenni E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Genetic determinants of response to clopidogrel and cardiovascular events. The New England journal of medicine. 2009. Simon Tabassome, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of the organic anion transporting polypeptide 1A2. Pharmacogenomics. 2009. Franke Ryan M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Redox regulation of multidrug resistance in cancer chemotherapy: molecular mechanisms and therapeutic opportunities. Antioxidants & redox signaling. 2009. Kuo Macus Tien. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology. 2008. Luna-Tortós Carlos, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS study. Pharmacogenetics and genomics. 2008. Donnelly Louise A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction. European heart journal. 2008. Regieli Jakub J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER. Atherosclerosis. 2008. Polisecki Eliana, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Interactions between the single nucleotide polymorphisms in the homocysteine pathway (MTHFR 677C>T, MTHFR 1298 A>C, and CBSins) and the efficacy of HMG-CoA reductase inhibitors in preventing cardiovascular disease in high-risk patients of hypertension: the GenHAT study. Pharmacogenetics and genomics. 2008. Maitland-van der Zee Anke-Hilse, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Machine learning methods and docking for predicting human pregnane X receptor activation. Chemical research in toxicology. 2008. Khandelwal Akash, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Combined treatment with statins and aminobisphosphonates extends longevity in a mouse model of human premature aging. Nature medicine. 2008. Varela Ignacio, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica; the fate of foreign compounds in biological systems. 2008. Zhou S-F. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. Xenobiotica; the fate of foreign compounds in biological systems. 2008. Hagenbuch B, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Polymorphisms of the HNF1A gene encoding hepatocyte nuclear factor-1 alpha are associated with C-reactive protein. American journal of human genetics. 2008. Reiner Alexander P, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment. Circulation. 2008. Krauss Ronald M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response. Circulation. Cardiovascular genetics. 2008. Voora Deepak, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis rate. Pharmacogenetics and genomics. 2008. Pasanen Marja K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Statins inhibit toll-like receptor 4-mediated lipopolysaccharide signaling and cytokine expression. Pharmacogenetics and genomics. 2008. Hodgkinson Conrad P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenetics and genomics. 2008. Deng Jian Wei, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association between ADAMTS1 matrix metalloproteinase gene variation, coronary heart disease, and benefit of statin therapy. Arteriosclerosis, thrombosis, and vascular biology. 2008. Sabatine Marc S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The functional consequences of genetic variations in transporter genes encoding human organic anion-transporting polypeptide family members. Expert opinion on drug metabolism & toxicology. 2008. Seithel Annick, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. Journal of the American College of Cardiology. 2008. Iakoubova Olga A, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study. Journal of the American College of Cardiology. 2008. Iakoubova Olga A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron. 2008. Uhr Manfred, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: a pilot study. Pharmacological research : the official journal of the Italian Pharmacological Society. 2008. Nikisch Georg, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacokinetic interaction between pravastatin and olmesartan in relation to SLCO1B1 polymorphism. Journal of human genetics. 2008. Suwannakul Suttasinee, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Long-term follow-up of the West of Scotland Coronary Prevention Study. The New England journal of medicine. 2007. Ford Ian, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
SLCO1B1 521T-->C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients. British journal of clinical pharmacology. 2007. Zhang Wei, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients. Journal of lipid research. 2007. Singer Jonathan B, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics of statin response. Current opinion in lipidology. 2007. Mangravite Lara M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants. Pharmacogenetics and genomics. 2007. Ho Richard H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Zetia: inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia. Journal of atherosclerosis and thrombosis. 2007. Davis Harry R, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Pharmacogenetic study of cholesteryl ester transfer protein gene and simvastatin treatment in hypercholesterolaemic subjects. Expert opinion on pharmacotherapy. 2007. Anagnostopoulou Katherine, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Physiogenomic association of statin-related myalgia to serotonin receptors. Muscle & nerve. 2007. Ruaño Gualberto, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin. Pharmacological research : the official journal of the Italian Pharmacological Society. 2007. Zuccaro Piergiorgio, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. The Journal of pharmacology and experimental therapeutics. 2007. Faucette Stephanie R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Asp92Asn polymorphism in the myeloid IgA Fc receptor is associated with myocardial infarction in two disparate populations: CARE and WOSCOPS. Arteriosclerosis, thrombosis, and vascular biology. 2006. Iakoubova Olga A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Cobalamin potentiates vinblastine cytotoxicity through downregulation of mdr-1 gene expression in HepG2 cells. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology. 2007. Marguerite Véronique, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Mechanism of inhibition of P-glycoprotein mediated efflux by vitamin E TPGS: influence on ATPase activity and membrane fluidity. Molecular pharmaceutics. 2007. Collnot Eva-Maria, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics. Pharmacogenetics and genomics. 2006. Niemi Mikko, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clinical pharmacology and therapeutics. 2006. Niemi Mikko, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle & nerve. 2006. Vladutiu Georgirene D, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes. British journal of clinical pharmacology. 2006. Hedman Mia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo. Cancer research. 2006. Leggas Markos, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clinical pharmacology and therapeutics. 2006. Neuvonen Pertti J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Impact of P-glycoprotein on clopidogrel absorption. Clinical pharmacology and therapeutics. 2006. Taubert Dirk, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin. Clinical pharmacology and therapeutics. 2006. Igel Michael, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Single nucleotide polymorphisms in human P-glycoprotein: its impact on drug delivery and disposition. Expert opinion on drug delivery. 2006. Dey Surajit. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The -514C/T polymorphism of the hepatic lipase gene significantly modulates the HDL-cholesterol response to statin treatment. Atherosclerosis. 2005. Lahoz Carlos, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
TaqIB polymorphism in CETP gene: the influence on incidence of cardiovascular disease in statin-treated patients with familial hypercholesterolemia. European journal of human genetics : EJHG. 2005. Mohrschladt Martina F, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17. Pharmacogenetics and genomics. 2005. Niemi Mikko, et al. PubMed
Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenetics and genomics. 2005. Kameyama Yoshio, et al. PubMed
An association study of 43 SNPs in 16 candidate genes with atorvastatin response. The pharmacogenomics journal. 2005. Thompson J F, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics. 2004. Niemi Mikko, et al. PubMed
Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA : the journal of the American Medical Association. 2004. Chasman Daniel I, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Influence of lipid lowering fibrates on P-glycoprotein activity in vitro. Biochemical pharmacology. 2004. Ehrhardt Manuela, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The microsomal triglyceride transfer protein gene-493T variant lowers cholesterol but increases the risk of coronary heart disease. Circulation. 2004. Ledmyr Helena, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clinical pharmacology and therapeutics. 2004. Mwinyi Jessica, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Haplotypes and SNPs in 13 lipid-relevant genes explain most of the genetic variance in high-density lipoprotein and low-density lipoprotein cholesterol. Human molecular genetics. 2004. Knoblauch Hans, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Interactions of human P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin. Pharmaceutical research. 2004. Hochman Jerome H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics. 2004. Kivistö Kari T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clinical pharmacology and therapeutics. 2004. Marzolini Catia, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
The cholesteryl ester transfer protein Taq1B gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease. American heart journal. 2003. Carlquist John F, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Interleukin-1B genotype modulates the improvement of coronary artery reactivity by lipid-lowering therapy with pravastatin: a placebo-controlled positron emission tomography study in young healthy men. Pharmacogenetics. 2003. Lehtimäki Terho, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clinical pharmacology and therapeutics. 2003. Nishizato Yohei, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events. Circulation. 2003. Boekholdt S Matthijs, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
DD ACE gene polymorphism is associated with increased coronary artery endothelial dysfunction: the PREFACE trial. Heart (British Cardiac Society). 2003. Mulder H J G H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Genetic polymorphisms of the human MDR1 drug transporter. Annual review of pharmacology and toxicology. 2003. Schwab Matthias, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Association of the factor XII 46C>T polymorphism with risk of coronary heart disease (CHD) in the WOSCOPS study. Atherosclerosis. 2002. Zito Francesco, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A cell-based reporter gene assay for determining induction of CYP3A4 in a high-volume system. The Journal of pharmacology and experimental therapeutics. 2002. Raucy Judy, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Interleukin-6 -174G>C polymorphism and risk of coronary heart disease in West of Scotland coronary prevention study (WOSCOPS). Arteriosclerosis, thrombosis, and vascular biology. 2002. Basso Federica, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The platelet Pl(A2) and angiotensin-converting enzyme (ACE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarction. The American journal of cardiology. 2001. Bray P F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn-Schmiedeberg's archives of pharmacology. 2001. Pauli-Magnus C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Increased risk for ischaemic events is related to combined RAS polymorphism. Heart (British Cardiac Society). 2001. van Geel P P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharmaceutics & drug disposition. 2000. Cohen L H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Short-term pravastatin mediates growth inhibition and apoptosis, independently of Ras, via the signaling proteins p27Kip1 and P13 kinase. Journal of the American Society of Nephrology : JASN. 1999. Weiss R H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. The Journal of clinical investigation. 1999. Greiner B, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pravastatin, an HMG-CoA reductase inhibitor, is transported by rat organic anion transporting polypeptide, oatp2. Pharmaceutical research. 1999. Tokui T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. The Journal of biological chemistry. 1999. Hsiang B, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis. The American journal of cardiology. 1999. de Maat M P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annual review of pharmacology and toxicology. 1999. Ambudkar S V, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
-455G/A polymorphism of the beta-fibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men: proposed role for an acute-phase reaction pattern of fibrinogen. REGRESS group. Arteriosclerosis, thrombosis, and vascular biology. 1998. de Maat M P, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. The New England journal of medicine. 1998. Kuivenhoven J A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Competitive, non-competitive and cooperative interactions between substrates of P-glycoprotein as measured by its ATPase activity. Biochimica et biophysica acta. 1997. Litman T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy. Atherosclerosis. 1995. Ordovas J M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
P-glycoprotein structure and evolutionary homologies. Cytotechnology. 1993. Croop J M. PubMed

LinkOuts

Web Resource:
Wikipedia
National Drug Code Directory:
0003-5154-05
DrugBank:
DB00175
KEGG Compound:
C01844
PubChem Compound:
54687
PubChem Substance:
192211
46504851
Drugs Product Database (DPD):
2247008
BindingDB:
20688
ChemSpider:
49398
Therapeutic Targets Database:
DAP000550
FDA Drug Label at DailyMed:
897ad8b7-921d-eb02-a61c-3419e662a2da

Clinical Trials

These are trials that mention pravastatin and are related to either pharmacogenetics or pharmacogenomics.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, Open Eye Scientific Software.